Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis

American Heart Journal

Volumn 168, Issue 4, 2014, Pages 530-536

  Alexopoulos, Dimitrios ^a   Xanthopoulou, Ioanna ^a   Storey, Robert F ^b   Bliden, Kevin P ^c   Tantry, Udaya S ^c   Angiolillo, Dominick J ^d   Gurbel, Paul A ^c  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; AGE; ARTICLE; BODY MASS; DIABETES MELLITUS; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; PLATELET REACTIVITY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG EFFECTS; THROMBOCYTE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; BLOOD PLATELETS; HUMANS; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 84922242655     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.06.026     Document Type: Article

References (33)

1. P.A. Gurbel, K.P. Bliden, and B.L. Hiatt Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
2. S.S. Brar, J. ten Berg, and R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
3. U.S. Tantry, L. Bonello, and D. Aradi Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
4. T. Geisler, D. Grass, and B. Bigalke The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
5. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
6. A.L. Frelinger III, D.L. Bhatt, and R.D. Lee Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function J Am Coll Cardiol 61 2013 872 879
7. P.A. Gurbel, K.P. Bliden, and D.K. Logan The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study J Am Coll Cardiol 62 2013 505 512
8. G. Cayla, T. Cuisset, and J. Silvain Prasugrel monitoring and bleeding in real world patients Am J Cardiol 111 2013 38 44
9. D. Alexopoulos, I. Xanthopoulou, and A. Perperis Factors affecting residual platelet aggregation in prasugrel treated patients Curr Pharm Des 19 2013 5121 5126
10. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: the ONSET/OFFSET Study Circulation 120 2009 2577 2585
11. R.F. Storey, D.J. Angiolillo, and S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
12. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
13. D. Alexopoulos, A. Galati, and I. Xanthopoulou Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study J Am Coll Cardiol 60 2012 193 199
14. D. Alexopoulos, I. Xanthopoulou, and E. Mavronasiou Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes mellitus Diabetes Care 36 2013 2211 2216
15. D. Alexopoulos, I. Xanthopoulou, and A. Siapika Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients Int J Cardiol 168 2013 629 630
16. D. Alexopoulos, I. Xanthopoulou, and P. Davlouros Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients J Thromb Haemost 11 2013 381 384
17. D. Alexopoulos, I. Xanthopoulou, and K. Stavrou Platelet reactivity measurements reveal patient noncompliance during ticagrelor maintenance therapy Can J Cardiol 29 2013 1743.e13 1743.e14
18. M. Laine, R. Toesca, and J. Berbis Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention Thromb Res 132 2013 e15 e18
19. Y.H. Jeong, K.P. Bliden, and U.S. Tantry High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost 10 2012 487 489
20. J.A. Jakubowski, C. Zhou, and B. Egan Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism Platelets 22 2011 619 625
21. Y.H. Jeong, K.P. Bliden, and M.J. Antonino Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 164 2012 35 42
22. R. Teng, P. Mitchell, and K. Butler Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals Eur J Clin Pharmacol 68 2012 1175 1182
23. S. Husted, H. Emanuelsson, and S. Heptinstall Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
24. S. Husted, S. James, and R.C. Becker Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial Circ Cardiovasc Qual Outcomes 5 2012 680 688
25. H. Wagner, D.J. Angiolillo, and J.M. Ten Berg Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients J Thromb Thrombolysis 2013 10.1007/s11239-013-0987-8 [Epub ahead of print]
26. N. Bonello-Palot, S. Armero, and F. Paganelli Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention Am J Cardiol 104 2009 1511 1515
27. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
28. R.C. Becker, J.P. Bassand, and A. Budaj Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial Eur Heart J 32 2011 2933 2944
29. J.H. Cornel, R.C. Becker, and S.G. Goodman Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J 164 2012 334 342
30. P.A. Gurbel, B.A. Baker, and W.L. Bailey Unraveling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 111 2014 1187 1190
31. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 2005 2430 2435
32. S. James, D.J. Angiolillo, and J.H. Cornel Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial Eur Heart J 31 2010 3006 3016
33. L. Bonello, M. Laine, and N. Kipson Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome J Am Coll Cardiol 63 2014 872 877